Drug Trial Radar · NCT02109627
Ficlatuzumab With High Dose Cytarabine in Relapsed and Refractory AML
Last checked: Nov 20, 2026Latest source record: Mar 24, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
17
Actual
Start
May 1, 2015
Primary completion
Dec 2, 2019
Study completion Dec 2, 2019
Sponsor
- Lead sponsor
- C. Babis AndreadisAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- AVEO Pharmaceuticals, Inc.; Gateway for Cancer Research
- First posted
- Apr 10, 2014
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to see if ficlatuzumab when combined with cytarabine, a standard treatment for AML, is safe to give to patients and to determine the best dose to give. The study doctors want to see what effects, good and/or bad, the study drug has on subjects and their AML. The study will look at what side effects subjects may have and how subjects feel after receiving the study drug.
Conditions
- Acute Myeloid Leukemia
- Relapsed Acute Myeloid Leukemia
- Refractory Acute Myeloid Leukemia
Interventions
FiclatuzumabDrug
5-20 mg/kg; intravenous; Days 0, 14, 28, and 42. Number of cycles: until progression or unacceptable toxicity develops.
CytarabineDrug
2 g/m2; intravenous; Days 2-7; Number of cycles: until progression or unacceptable toxicity develops.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose-Limiting Toxicity (DLT) for ficlatuzumab when administered with HiDACTime frame: Up to 2 years
- Maximum Tolerated Dose (MTD) for ficlatuzumab when administered with HiDACTime frame: Up to 2 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University of California, San Francisco
San Francisco, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.